Skip to main content
SpringerLink
Log in

Pathophysiology and Treatment of Psychosis in Parkinson’s Disease

A Review

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Psychotic symptoms in Parkinson’s disease (PD) are relatively common and, in addition to creating a disturbance in patients’ daily lives, have consistently been shown to be associated with poor outcome. Our understanding of the pathophysiology of psychosis in PD has expanded dramatically over the past 15 years, from an initial interpretation of symptoms as dopaminergic drug adverse effects to the current view of a complex interplay of extrinsic and disease-related factors.

PD psychosis has unique clinical features, namely that it arises within a context of a clear sensorium and retained insight, there is relative prominence of visual hallucinations and progression occurs over time. PD psychosis tends to emerge later in the disease course, and disease duration represents one risk factor for its development. The use of anti-PD medications (particularly dopamine receptor agonists) has been the most widely identified risk factor for PD psychosis. Other risk factors discussed in the literature include older age, disease severity, sleep disturbance, cognitive impairment, dementia and/or depression.

Recent efforts have aimed to explore the complex pathophysiology of PD psychosis, which is now known to involve an interaction between extrinsic, drug-related and intrinsic, disease-related components. The most important extrinsic factor is use of dopaminergic medication, which plays a prominent role in PD psychosis. Intrinsic factors include visual processing deficits (e.g. lower visual acuity, colour and contrast recognition deficits, ocular pathology and functional brain abnormalities identified amongst hallucinating PD patients); sleep dysregulation (e.g. sleep fragmentation and altered dream phenomena); neurochemical (dopamine, serotonin, acetylcholine, etc.) and structural abnormalities involving site-specific Lewy body deposition; and genetics (e.g. apolipoprotein E ɛ4 allele and tau H1H1 genotype). Preliminary reports have also shown a potential relationship between deep brain stimulation surgery and PD psychosis.

When reduction in anti-PD medications to the lowest tolerated dose does not improve psychosis, further intervention may be warranted. Several atypical antipsychotic agents (i.e. clozapine, olanzapine) have been shown to be efficacious in reducing psychotic symptoms in PD; however, use of clozapine requires cumbersome monitoring and olanzapine leads to motor worsening. Studies of ziprasidone and aripiprazole are limited to open-label trials and case reports and are highly variable; however, it appears that while each may be effective in some patients, both are associated with adverse effects. While quetiapine has not been determined efficacious in two randomized controlled trials, it is a common first-line treatment for PD psychosis because of its tolerability, ease of use and demonstrated utility in numerous open-label reports. Cholinesterase inhibitors currently represent the most promising pharmacological alternative to antipsychotics. Tacrine is rarely tried because of hepatic toxicity, and controlled trials with donepezil have not shown significant reductions in psychotic symptoms, due perhaps to methodological limitations. However, results from an open-label study and a double-blind, placebo-controlled trial involving 188 hallucinating PD patients support the efficacy of rivastigmine. With regard to non-pharmacological interventions, case reports suggest that electroconvulsive therapy has the potential to reduce psychotic symptoms and may be considered in cases involving concurrent depression and/or medication-refractory psychosis. Limited case reports also suggest that specific antidepressants (i.e. clomipramine and citalopram) may improve psychosis in depressed patients. Finally, studies in the schizophrenia literature indicate that psychological approaches are effective in psychosis management but, to date, this strategy has been supported only qualitatively in PD, and further studies are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002 Aug 13; 59(3): 408–13

    Article  PubMed  Google Scholar 

  2. Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 2002; 17: 60–7

    Article  Google Scholar 

  3. Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Parkinson’s Study Group. Mov Disord 1998; 13: 20–8

    Article  PubMed  CAS  Google Scholar 

  4. Aarsland D, Larsen JP, Tandbert E. Predictors of nursing home placement in PD: a population-based prospective study. J Am Geriatr Soc 2000; 48: 938–42

    PubMed  CAS  Google Scholar 

  5. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 1993; 43: 2227–9

    Article  PubMed  CAS  Google Scholar 

  6. Fenelon G, Mahieux F, Huron R, et al. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000 Apr; 123 (Pt 4): 733–45

    Article  PubMed  Google Scholar 

  7. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996 Dec; 53(12): 1265–8

    Article  PubMed  CAS  Google Scholar 

  8. American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 4th rev. ed. Washington, DC: American Psychiatric Association, 2000

    Google Scholar 

  9. Kendler KS, Gallagher TJ, Abelson JM, et al. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: the National Comorbidity Survey. Arch Gen Psychiatry 1996; 53: 1022–31

    Article  PubMed  CAS  Google Scholar 

  10. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS/NIMH work group. Mov Disord 2007 Jun 15; 22(8): 1061–8

    Article  PubMed  Google Scholar 

  11. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 64: 533–5

    Article  PubMed  CAS  Google Scholar 

  12. Factor SA, Molho ES. Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. Clin Neuropharmacol 2004; 27: 205–7

    Article  PubMed  Google Scholar 

  13. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63: 293–300

    Article  PubMed  CAS  Google Scholar 

  14. Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry 2001; 16: 528–36

    Article  PubMed  CAS  Google Scholar 

  15. Sadock BJ, Sadock VA, editors. Kaplan and Sadock’s comprehensive textbook of psychiatry. 8th rev. ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2004

    Google Scholar 

  16. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2001; 70: 734–8

    Article  PubMed  CAS  Google Scholar 

  17. Kiziltan G, Ozekmekci S, Ertan S, et al. Relationship between age and subtypes of psychotic symptoms in Parkinson’s disease. J Neurol 2007 Apr; 254(4): 448–52

    Article  PubMed  Google Scholar 

  18. Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord 2008; 23(4): 484–500

    Article  PubMed  Google Scholar 

  19. Wolters EC, Berendse HW. Management of psychosis in Parkinson’s disease. Curr Opin Neurol 2001; 14: 499–504

    Article  PubMed  CAS  Google Scholar 

  20. Goetz CG, Fan W, Leurgans S, et al. The malignant course of “benign hallucinations” in Parkinson disease. Arch Neurol 2006; 63: 713–6

    Article  PubMed  Google Scholar 

  21. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135: 669–75

    PubMed  CAS  Google Scholar 

  22. Pappert EJ, Goetz CG, Niederman FG, et al. Sleep fragmentation, and altered dream phenomena in PD. Mov Disord 1999; 14: 117–21

    Article  PubMed  CAS  Google Scholar 

  23. Aarsland D, Larsen JP, Cummins JL, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56(5): 595–601

    Article  PubMed  CAS  Google Scholar 

  24. Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm 2004; 111(10–11): 1447–53

    Article  PubMed  CAS  Google Scholar 

  25. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression, and psychosis in long-standing Parkinson’s disease. J Neural Transm 2000; 107(1): 59–71

    Article  PubMed  CAS  Google Scholar 

  26. Doe De Maindreville A, Fenelon G, Mahieux F. Hallucinations in Parkinson’s disease: a follow-up study. Mov Disord 2005 Feb; 20(2): 212–7

    Article  Google Scholar 

  27. Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson’s disease. J Neurol 2005 Oct; 252(10): 1223–8

    Article  PubMed  Google Scholar 

  28. Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991; 14: 283–95

    Article  PubMed  CAS  Google Scholar 

  29. Factor SA, Molho ES, Podskalny GD, et al. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol 1995; 65: 115–38

    PubMed  CAS  Google Scholar 

  30. Glenthøj BY, Hemmingsen R. Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Prog Neuro-psychopharmacol Biol Psychiatry 1997; 21: 23–46

    Article  Google Scholar 

  31. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157(4): 514–20

    Article  PubMed  CAS  Google Scholar 

  32. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982; 139(4): 494–7

    PubMed  CAS  Google Scholar 

  33. Fox SH, Visanji NP, Johnston TH, et al. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 2006 Sept; 63: 1343–4

    Article  PubMed  Google Scholar 

  34. Chan DK. The art of treating Parkinson disease in the older patient. Aust Fam Physician 2003 Nov; 32(11): 927–31

    PubMed  Google Scholar 

  35. Wolters EC. Intrinsic and extrinsic psychosis in Parkinson’s disease. J Neurol 2001; 248Suppl. 3: III/22–7

    Google Scholar 

  36. Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology 2006; 66: 93–8

    Article  PubMed  Google Scholar 

  37. Rondot P, de Recondo J, Coignet A, et al. Mental disorders in Parkinson’s disease after treatment with L-DOPA. Adv Neurol 1984; 40: 259–69

    PubMed  CAS  Google Scholar 

  38. Tanner CM, Vogel C, Goetz CG, et al. Hallucinations in Parkinson’s disease: a population study [abstract]. Ann Neurol 1983; 12: 136

    Google Scholar 

  39. Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc 1975 May; 23(5): 212–5

    PubMed  CAS  Google Scholar 

  40. Klein C, Kompf D, Pulkowski U, et al. A study of visual hallucinations in patients with Parkinson’s disease. J Neurol 2007 Jun; 244(6): 371–7

    Article  Google Scholar 

  41. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998; 50: 515–7

    Article  PubMed  CAS  Google Scholar 

  42. Diedrich NJ, Goetz CG, Raman R, et al. Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol 1998; 21: 289–95

    Google Scholar 

  43. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients. Trends Neurosci 1990 Jul; 13(7): 296–302

    Article  PubMed  CAS  Google Scholar 

  44. Maurage CA, Ruchoux MM, de Vos R, et al. Retinal involvement in dementia with Lewy bodies: a clue to hallucinations? Ann Neurol 2003; 54: 542–7

    Article  PubMed  Google Scholar 

  45. Onofrj M, Bonanni L, Albani G, et al. Visual hallucinations in Parkinson’s disease: clues to separate origins. J Neurol Sci 2006; 248: 143–50

    Article  PubMed  CAS  Google Scholar 

  46. Kraft E, Winkelmann J, Trenkwalder C, et al. Visual hallucinations: white matter lesions and disease severity in Parkinson’s disease. Acta Neurol Scand 1999; 98: 1–6

    Google Scholar 

  47. Stebbins GT, Goetz CG, Carillo MC, et al. Altered cortical visual processing in PD with hallucinations. Neurology 2004; 63: 1409–16

    Article  PubMed  CAS  Google Scholar 

  48. Holroyd S, Wooten GF. Preliminary fMRI evidence of visual system dysfunction in Parkinson’s disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci 2006; 18(3): 402–4

    Article  PubMed  Google Scholar 

  49. Barnes J, Boubert L, Harris J, et al. Reality monitoring and visual hallucinations in Parkinson’s disease. Neuropsychologia 2003; 41: 565–74

    Article  PubMed  CAS  Google Scholar 

  50. Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson’s disease. CNS Drugs 2001; 15(4): 267–75

    Article  PubMed  CAS  Google Scholar 

  51. Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Movement Disorders 2005; 20(11): 1439–48

    Article  PubMed  Google Scholar 

  52. Cornelia CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 1993; 34: 710–4

    Article  Google Scholar 

  53. Arnulf I, Knofal E, Merino-Andreu M, et al. Parkinson’s disease and sleepiness: an integral part of PD. Neurology 2002; 58: 1019–24

    Article  PubMed  CAS  Google Scholar 

  54. Perry E, Walker M, Grace J, et al. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999; 22: 273–80

    Article  PubMed  CAS  Google Scholar 

  55. Zoldan J, Friedberg G, Goldberg-Stern H, et al. Ondansetron for hallucinosis in advanced Parkinson’s disease. Lancet 1993; 341(8844): 562–3

    Article  PubMed  CAS  Google Scholar 

  56. Zoldan J, Friedberg G, Livneh M, et al. Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45(7): 1305–8

    Article  PubMed  CAS  Google Scholar 

  57. Van der Mast RC, Fekkes D. Serotonin and amino acids: partners in delirium pathophysiology? Semin Clin Neuropsychiatry 2000; 5(2): 125–31

    PubMed  Google Scholar 

  58. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm 1975; 37(2): 175–82

    Article  PubMed  CAS  Google Scholar 

  59. Nausieda PA, Tanner CM, Klawans HL. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv Neurol 1983; 37: 23–32

    PubMed  CAS  Google Scholar 

  60. Melamed E, Zoldan J, Friedberg G, et al. Involvement of serotonin in clinical features of Parkinson’s disease and complications of L-DOPA therapy. Adv Neurol 1996; 69: 545–50

    PubMed  CAS  Google Scholar 

  61. Whitehouse PJ. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson’s disease and Alzheimer’s disease. Adv Neurol 1987; 45: 393–7

    PubMed  CAS  Google Scholar 

  62. Kuhl DE, Minoshima S, Fessier JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol 1996; 40(3): 399–410

    Article  PubMed  CAS  Google Scholar 

  63. Zahodne LB, Fernandez HH. Course, prognosis, and management of psychosis in Parkinson’s disease: are current treatments really effective? CNS Spectrums 2008; 13 (3 Suppl. 4): 26–33

    PubMed  Google Scholar 

  64. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002 Feb 1; 125(2): 391–403

    Article  PubMed  CAS  Google Scholar 

  65. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605–10

    Article  PubMed  Google Scholar 

  66. Papapetropoulos S, McCorquodale DS, Gonzalez J, et al. Cortical and amygdalar Lewy body burden in Parkinson’s disease patients with visual hallucinations. Parkinsonism Relat Disord 2006 May; 12(4): 253–6

    Article  PubMed  Google Scholar 

  67. Paleacu D, Schechtman E, Inzelberg R. Association between family history of dementia and hallucinations in Parkinson disease. Neurology 2005 May; 64(10): 1712–5

    Article  PubMed  Google Scholar 

  68. De la Fuente-Fernandez R, Nunez MA, Lopez E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson’s disease. Clin Neuropharmacol 1999 Jul–Aug; 22(4): 226–30

    PubMed  Google Scholar 

  69. Feldman B, Chapman J, Korczyn AD. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson’s disease. Acta Neurol Scand 2006 Jan; 113(1): 14–7

    Article  PubMed  CAS  Google Scholar 

  70. Goetz CG, Burke PF, Leurgans S, et al. Genetic variation analysis in Parkinson disease patients with and without hallucinations: case-control study. Arch Neurol 2001 Feb; 58(2): 209–13

    Article  PubMed  CAS  Google Scholar 

  71. Camicioli R, Rajput A, Rajput M, et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson’s disease: relationship to dementia and hallucinations. Mov Disord 2005 Aug; 20(8): 989–94

    Article  PubMed  Google Scholar 

  72. Papapetropoulos S, Farrer MJ, Stone JT, et al. Phenotypic associations of tau and ApoE in Parkinson’s disease. Neurosci Lett 2007; 414: 141–4

    Article  PubMed  CAS  Google Scholar 

  73. Chen CC, Lee ST, Wu T, et al. Short-term effects of bilateral subthalamic stimulation for advanced Parkinson’s disease. Chang Gung Med J 2003 May; 26(5): 344–51

    PubMed  Google Scholar 

  74. Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease. Mov Disord 2003 Nov; 18(11): 1332–7

    Article  PubMed  Google Scholar 

  75. Castelli L, Perozzo P, Zibetti M, et al. Chronic deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: effects on cognition, mood, anxiety and personality traits. Eur Neurol 2006; 55(3): 136–44

    Article  PubMed  CAS  Google Scholar 

  76. Vesper J, Haak S, Ostertag C, et al. Subthalamic nucleus deep brain stimulation in elderly patients: analysis of outcome and complications. BMC Neurol 2007 Mar 16; 7: 7

    Article  PubMed  Google Scholar 

  77. Wint DP, Okun MS, Fernandez HH. Psychosis in Parkinson’s disease. J Geriatr Psychiatry Neurol 2004; 1793): 127–36

    Article  PubMed  Google Scholar 

  78. Goetz CG, Vogel C, Tanner CM, et al. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998; 51(3): 811–4

    Article  PubMed  CAS  Google Scholar 

  79. Henderson MJ, Meilers JDC. Psychosis in Parkinson’s disease: “between a rock and a hard place”. Int Rev Psychiatry 2000; 12: 319–34

    Article  Google Scholar 

  80. Fernandez HH, Friedman JF. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs 1999; 11(6): 467–83

    Article  CAS  Google Scholar 

  81. Friedman JH, Fernandez HH. The non-motor problems of Parkinson’s disease. Neurology 2000; 6: 18–27

    Article  Google Scholar 

  82. Noel JM. ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders. Am J Health Syst Pharm 2007; 64: 863–76

    Article  PubMed  CAS  Google Scholar 

  83. Keltner NL, Johnson V. Aripiprazole: a third generation of antipsychotics begins? Perspect Psychiatr Care 2002; 38(4): 157–9

    Article  PubMed  Google Scholar 

  84. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294(15): 1934–43

    Article  PubMed  CAS  Google Scholar 

  85. Goetz CG, Leurgans S, Pappert EJ, et al. Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 2001; 57: 2078–82

    Article  PubMed  CAS  Google Scholar 

  86. Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson’s disease. Mov Disord 2005; 20(1): 104–15

    Article  PubMed  Google Scholar 

  87. Frieling H, Hillemacher T, Ziegenbein M, et al. Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 2007 Feb; 17(3): 165–71

    Article  PubMed  CAS  Google Scholar 

  88. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40(5): 832–4

    Article  PubMed  CAS  Google Scholar 

  89. French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet 1999; 353(9169): 2041–2

    Article  Google Scholar 

  90. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340(10): 757–63

    Article  Google Scholar 

  91. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000; 151: 201–11

    Article  Google Scholar 

  92. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 2003; 60: 1756–61

    Article  PubMed  CAS  Google Scholar 

  93. Fernandez HH, Friedman JH, Lansang MC, et al. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism Relat Disord 2004; 10(7): 439–41

    Article  PubMed  Google Scholar 

  94. Klein C, Gordon J, Pollak L, et al. Clozapine in Parkinson’s disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003; 26(1): 8–11

    Article  PubMed  CAS  Google Scholar 

  95. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapinerelated morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59Suppl. 3: 3–7

    PubMed  Google Scholar 

  96. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75(5): 689–95

    Article  PubMed  CAS  Google Scholar 

  97. Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004; 21(6): 515–23

    Article  PubMed  CAS  Google Scholar 

  98. Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 43: 456–60

    Google Scholar 

  99. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52(4): 782–5

    Article  PubMed  CAS  Google Scholar 

  100. Rustembegovic A, Sofic E, Wichart I. Serum prolactin, leptin, lipids and lipoprotein levels during antipsychotic treatment in Parkinson’s disease and related psychosis. Med Arh 2006; 60(4): 211–2

    PubMed  Google Scholar 

  101. Ford B, Lynch T, Greene P. Risperidone in Parkinson’s disease [letter]. Lancet 1994; 344(8923): 681

    Article  PubMed  CAS  Google Scholar 

  102. McKeith IG, Ballard CG, Harrison RW. Neuroleptic sensitivity to risperidone in Lewy body dementia [letter]. Lancet 1995; 346(8976): 699

    Article  PubMed  CAS  Google Scholar 

  103. Allen RL, Walker Z, D’Ath PJ, et al. Risperidone for psychotic and behavioural symptoms in Lewy body dementia [letter]. Lancet 1995; 346(8968): 185

    Article  PubMed  CAS  Google Scholar 

  104. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson’s disease patients. Lancet 1994; 343(8909): 1370–1

    Article  PubMed  CAS  Google Scholar 

  105. Workman Jr RH, Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1997; 9(4): 594–7

    PubMed  CAS  Google Scholar 

  106. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56(12): 556–9

    PubMed  CAS  Google Scholar 

  107. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov Disord 2000; 15(6): 1230–7

    Article  PubMed  CAS  Google Scholar 

  108. Meco G, Alessandri A, Giustini P, et al. Risperidone in levodopa-induced psychosis in advanced Parkinson’s disease: an open-label, long-term study. Mov Disord 1997; 12(4): 610–2

    Article  PubMed  CAS  Google Scholar 

  109. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson’s disease [letter]. Mov Disord 2001; 12: 364–9

    Google Scholar 

  110. Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2000; 12(3): 364–9

    Article  PubMed  CAS  Google Scholar 

  111. Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 1992; 262(2): 545–51

    PubMed  CAS  Google Scholar 

  112. Wolters EC, Jansen EN, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 1996; 47(4): 1085–7

    Article  PubMed  CAS  Google Scholar 

  113. Fernandez HH, Trieschmann ME, Friedman JH. The treatment of psychosis in Parkinson’s disease: safety considerations. Drug Saf 2003; 26: 643–59

    Article  PubMed  CAS  Google Scholar 

  114. Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55(6): 789–94

    Article  PubMed  CAS  Google Scholar 

  115. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 2002; 52(5): 438–45

    Article  PubMed  CAS  Google Scholar 

  116. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17(5): 1031–5

    Article  PubMed  Google Scholar 

  117. Sailer CF, Salama AI. Seroquel: biochemical profile of a potential typical antipsychotic. Psychopharmacology (Berl) 1993; 112(2–3): 285–92

    Article  Google Scholar 

  118. Factor SA. Pharmacology of atypical antipsychotics. Clinical Neuropharmacol 2002; 25(3): 153–7

    Article  CAS  Google Scholar 

  119. Borison RL, Arvanitis LA, Miller BD. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16(2): 158–69

    Article  PubMed  CAS  Google Scholar 

  120. Reddy S, Factor SA, Molho ES, et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17(4): 676–81

    Article  PubMed  Google Scholar 

  121. Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18(5): 510–4

    Article  PubMed  Google Scholar 

  122. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 2005; 20(8): 958–63

    Article  PubMed  Google Scholar 

  123. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 2007; 22(3): 313–8

    Article  PubMed  Google Scholar 

  124. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27(4): 153–6

    Article  PubMed  CAS  Google Scholar 

  125. Klein C, Prokhorov T, Miniovich A, et al. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol 2006; 29(4): 215–9

    Article  PubMed  CAS  Google Scholar 

  126. Juri C, Chana P, Tapia J, et al. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol 2005; 28: 185–7

    Article  PubMed  CAS  Google Scholar 

  127. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003; 64Suppl. 19: 6–12

    Google Scholar 

  128. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005; 66Suppl. 6: 5–10

    PubMed  Google Scholar 

  129. Connemann BJ, Schonfeldt-Lecuona C. Ziprasidone in Parkinson’s disease psychosis [letter]. Can J Psychiatry 2004; 49(1): 73

    PubMed  Google Scholar 

  130. Shiah I-S, Lin C-L, Mao W-C, et al. Ziprasidone in the treatment of Parkinson’s disease psychosis. Eur Psychiatry 2006; 21: 578–9

    Article  PubMed  Google Scholar 

  131. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005; 28(3): 111–4

    Article  PubMed  CAS  Google Scholar 

  132. Oechsner M, Korchounov A. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson’s disease? Hum Psychopharmacol 2005; 20(3): 203–5

    Article  PubMed  Google Scholar 

  133. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract 2002; 8(2): 81–97

    Article  PubMed  Google Scholar 

  134. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002; 16(11): 779–86

    Article  PubMed  CAS  Google Scholar 

  135. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: “Goldilocks” actions at dopamine receptors. J Clin Psychiatry 2001 Nov; 62(11): 841–2

    Article  PubMed  CAS  Google Scholar 

  136. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001 Dec; 62(12): 923–4

    Article  PubMed  CAS  Google Scholar 

  137. Schonfeldt-Lecuona C, Connemann BJ. Aripiprazole and Parkinson’s disease psychosis. Am J Psychiatry 2004; 161: 373–4

    Article  PubMed  Google Scholar 

  138. Wickremaratchi M, Morris HR. Aripiprazole associated with severe exacerbation of Parkinson’s disease. Mov Disord 2006; 21(9): 1538–9

    Article  PubMed  Google Scholar 

  139. Lopez-Meza E, Ruiz-Chow A, Ramirez-Bermudez J. Aripiprazole in psychosis associated with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2005; 17(3): 421–2

    Article  PubMed  CAS  Google Scholar 

  140. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004; 27: 4–5

    Article  PubMed  CAS  Google Scholar 

  141. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord 2006; 21(12): 2078–81

    Article  PubMed  Google Scholar 

  142. Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996; 47(6): 1608–9

    Article  PubMed  CAS  Google Scholar 

  143. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1996; 61(3): 324–5

    Article  PubMed  CAS  Google Scholar 

  144. Ott B, Lannon M. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol 1992; 15(4): 322–5

    Article  PubMed  CAS  Google Scholar 

  145. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci 2002; 23(1): 41–3

    Article  PubMed  CAS  Google Scholar 

  146. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol 2002; 25(2): 107–10

    Article  PubMed  CAS  Google Scholar 

  147. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J Geriatr Psychiatry Neurol 2003; 16(3): 184–8

    Article  PubMed  Google Scholar 

  148. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76(7): 934–9

    Article  PubMed  CAS  Google Scholar 

  149. Aarsland D, Laake K, Larsen J, et al. Donepezil for cognitive impairment in Parkinson’s disease: a randomized controlled study. J. Neurol Neurosurg Psychiatry 2002; 72: 708–12

    Article  CAS  Google Scholar 

  150. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003; 18: 937–41

    Article  PubMed  CAS  Google Scholar 

  151. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171–4

    Article  PubMed  CAS  Google Scholar 

  152. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin 2002; 18(5): 258–64

    Article  PubMed  CAS  Google Scholar 

  153. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006; 21(11): 1899–907

    Article  PubMed  Google Scholar 

  154. Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1995; 7(3): 304–7

    PubMed  CAS  Google Scholar 

  155. Hurwitz TA, Calne DB, Waterman K. Treatment of dopamimetic psychosis in Parkinson’s disease with electroconvulsive therapy. Can J Neurol Sci 1988; 15(1): 32–4

    PubMed  CAS  Google Scholar 

  156. Ozer F, Meral H, Aydin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT 2005 Jun; 21(2): 125–7

    Article  PubMed  Google Scholar 

  157. Lauterbach EC. Dopaminergic hallucinosis with fluoxetine in Parkinson’s disease [letter]. Am J Psychiatry 1993; 150(11): 1750

    PubMed  CAS  Google Scholar 

  158. Normann C, Hesslinger B, Frauenknecht S, et al. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 1997; 30(6): 263–5

    Article  PubMed  CAS  Google Scholar 

  159. Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prof Neuropsychopharmacol Biol Psychiatry 2007 Jan 30; 31(1): 311–3

    CAS  Google Scholar 

  160. Voon V, Lang AE. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin Neuropharmacol 2004; 27(2): 90–2

    Article  PubMed  Google Scholar 

  161. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson’s disease. Mov Disord 2003; 18(7): 831–8

    Article  PubMed  Google Scholar 

  162. McGorry PD. Psychoeducation in first-episode psychosis: a therapeutic process. Psychiatry 1995 Nov; 58(4): 313–28

    PubMed  CAS  Google Scholar 

  163. Tarrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? Behav Res Ther 2004 Dec; 42(12): 1377–407

    Article  PubMed  Google Scholar 

  164. Jenner JA, van de Willige G, Wiersma D. Effectiveness of cognitive therapy with coping training for persistent auditory hallucinations: a retrospective study of attenders of a psychiatric out-patient department. Acta Psychiatr Scand 1998 Nov; 98(5): 384–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No funding has been received for the conduct of this study and/or the preparation of this review.

Hubert Fernandez has, over the past 5 years, been a paid consultant, paid speaker or performed clinical research under contract to Amarin, Allergan, AstraZeneca, Aventis, Boehringer Ingelheim, Boston Life Sciences, Biogen Idec, Cephalon, Eisai, Elan, Forest Laboratories, GlaxoSmithKline, Huntington Study Group, Ipsen, Kyowa, Merck, Merz, Michael J. Fox Foundation, Mylan Bertek, National Parkinson Foundation, Neurotrax, National Institutes of Health/National Institute of Neurological Disorders and Stroke, Novartis, Parkinson Study Group, Society of Progressive Supranuclear Palsy, Solstice, Solvay, Teva, United Biosource Corporation, Valeant and Vernalis, but has no owner interest in any pharmaceutical company. Laura Zahodne has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA

    Laura B. Zahodne

  2. Movement Disorders Center, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA

    Laura B. Zahodne &  Hubert H. Fernandez

  3. Department of Neurology, University of Florida, Gainesville, Florida, USA

    Hubert H. Fernandez

Authors
  1. Laura B. Zahodne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hubert H. Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hubert H. Fernandez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zahodne, L.B., Fernandez, H.H. Pathophysiology and Treatment of Psychosis in Parkinson’s Disease. Drugs Aging 25, 665–682 (2008). https://doi.org/10.2165/00002512-200825080-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200825080-00004

Keywords

Search

Navigation